Contacts

Patsy Folio

CONTACT

1-240-415-6022 [email protected]

Transis Clemons

CONTACT

1-240-415-6038 [email protected]

Sponsors

Lead Sponsor

Biological Dynamics

Age

21 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Non-small cell lung: Male or Female Adult patient \>= 21 years old
•Breast only: Female Adult patient \>= 21 years old
•Previously diagnosed with one of the following cancers:
•Breast or Non-small Cell Lung
•Cancer has progressed to at least Stage III or higher for lung cancer or,
•Cancer has progressed to stage IV (metastatic) breast cancer
•Participating in standard of care cancer therapy requiring frequent treatments, typically intravenous chemotherapy visits (or as determined by the standard of care for the particular cancer assessed), of a minimum of three (3) treatment visits planned in 9 months from date of enrollment where a clinical assessment will be conducted

Exclusion Criteria

•Physician assessment that obtaining two extra whole blood specimens with minimum volume of 5 mL per treatment visit is contraindicated
•Stage I and II Non-small Cell Lung Cancer
•Stage I through III breast cancer
•Pregnant or planning to become pregnant during the course of the study
•Unable to obtain informed consent from subject or their legal representative
•Life expectancy is less than 9 months
•Presence of one or more of the following other chronic diseases
•Another type of cancer except for non-melanomatous skin tumors
•Autoimmune disease requiring DMARDS or Biologics
•Infectious disease requiring prolonged intravenous antibiotics or hospitalization
•Renal disease specifically those in End Stage Renal Failure
•Recent (\< 3 weeks) major trauma or major surgical procedure(s) or radiation therapy prior to enrollment in the study
•Recent (\< 2 months) major occlusive arterial event such as MI or CVA prior to enrollment in the study

Related studies

RECRUITINGPhase 2

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

NCT07287098 · Breast Neoplasms

RECRUITINGPhase 2

A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)

NCT06780085 · Carcinoma, Non-Small-Cell Lung

RECRUITINGPhase 2

PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)

NCT07222215 · Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer, and more

RECRUITINGPhase 2

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

NCT07489066 · Carcinoma, Non-Small-Cell Lung, and more

RECRUITING

A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting

NCT07230691 · Carcinoma, Non-Small-Cell Lung

View all related studies →

TR(ACE) Assay Clinical Specimen Study

What this study is about

Save this trial guide to your notes

Contacts

Sponsors

Related studies

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)

PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting

Trial snapshot

Condition

Locations shown

For caregivers